antiarrhythmic agents also known cardiac dysrhythmia medications group pharmaceuticals used suppress abnormally fast rhythms tachycardias atrial fibrillation supraventricular tachycardia ventricular tachycardia many attempts made classify antiarrhythmic agents many antiarrhythmic agents multiple modes action makes classification imprecise cardiac myocyte two general types action potentials conduction system working myocardium action potential divided phases shown diagram sharp rise voltage corresponds influx sodium ions whereas two decays respectively correspond sodiumchannel inactivation repolarizing efflux potassium ions characteristic plateau results opening voltagesensitive calcium channels phase utilizes different channels useful compare phases common classification system vaughan williams described vaughan williams introduced miles vaughan vaughan williams pharmacology tutor hertford college oxford one students bramah n contributed development classification system system therefore sometimes known singhvaughan williams classification five main classes vaughan williams classification antiarrhythmic agents regard management atrial fibrillation classes iii used rhythm control medical cardioversion agents classes ii iv used ratecontrol agents class prolongs action potential intermediate effect phase depolarization class shorten action potential myocardial cell weak effect initiation phase depolarization class affect action potential duration strongest effect initiation phase depolarization sotalol also beta amiodarone class iii mostly also ii iv class antiarrhythmic agents interfere sodium channel class agents grouped effect na channel effect cardiac action potentials class agents called membranestabilizing agents stabilizing referring decrease excitogenicity plasma membrane brought agents also noteworthy class ii agents like propranolol also membrane stabilizing effect class agents divided three groups ia ib ic based upon effect length action class ia class ib class ic class ii agents conventional beta blockers act blocking effects catecholamines receptors thereby decreasing sympathetic activity heart reduces intracellular camp levels hence reduces influx agents particularly useful treatment supraventricular tachycardias decrease conduction av node class ii agents include atenolol esmolol propranolol metoprolol class iii agents predominantly block potassium channels thereby prolonging since agents affect sodium channel conduction velocity decreased prolongation action potential duration refractory period combined maintenance normal conduction velocity prevent reentrant arrhythmias reentrant rhythm less likely interact tissue become refractory class iii agents exhibit reverseuse dependence potency increases slower heart rates therefore improves maintenance sinus rhythm inhibiting potassium channels results slowed atrialventricular myocyte repolarization class iii agents potential prolong qt interval ekg may proarrhythmic associated development polymorphic vt class iii agents include bretylium amiodarone ibutilide sotalol dofetilide vernakalant dronedarone class iv agents slow nondihydropyridine calcium channel blockers decrease conduction av node shorten phase two plateau cardiac action potential thus reduce contractility heart may inappropriate heart failure however contrast beta blockers allow body retain adrenergic control heart rate contractilitycitation needed class iv agents include verapamil diltiazem since development original vaughan williams classification system additional agents used fit cleanly categories iv agents include initial classification system classes although definitions different modern classification proposed another approach known sicilian gambit placed greater approach underlying presents drugs two axes instead one presented tabular form axis drug listed roughly singhvaughan williams order x axis channels receptors pumps clinical effects listed drug results listed grid therefore true classification aggregate drugs recent publication emerged fully modernised drug preserves simplicity original vaughan williams framework capturing subsequent discoveries sarcolemmal sarcoplasmic reticular cytosolic biomolecules result expanded pragmatic classification encompasses approved potential antiarrhythmic drugs aid understanding clinical management cardiac arrhythmias facilitate future therapeutic developments starts considering range pharmacological targets tracks particular cellular electrophysiological effects retains expands original vaughan williams classes iv respectively covering actions na current components autonomic signalling k channel subspecies molecular targets related homeostasis introduces new classes incorporating additional targets including also allows multiple drug targetsactions adverse proarrhythmic effects new scheme additionally aid development novel drugs development illustrated httpsenwikipediaorgwikiantiarrhythmicagent